{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:46:03Z","timestamp":1792741563502,"version":"4.5.0"},"reference-count":59,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2011,9,30]],"date-time":"2011-09-30T00:00:00Z","timestamp":1317340800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0025653","type":"journal-article","created":{"date-parts":[[2011,9,30]],"date-time":"2011-09-30T20:53:22Z","timestamp":1317416002000},"page":"e25653","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":58,"title":["Imaging Mass Spectrometry Reveals Elevated Nigral Levels of Dynorphin Neuropeptides in L-DOPA-Induced Dyskinesia in Rat Model of Parkinson's Disease"],"prefix":"10.1371","volume":"6","author":[{"given":"Anna","family":"Ljungdahl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Hanrieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"F\u00e4lth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Bergquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2011,9,30]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1111\/j.1468-1331.2009.02697.x","article-title":"Levodopa in the treatment of Parkinson's disease.","volume":"16","author":"AH Schapira","year":"2009","journal-title":"Eur J Neurol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1159\/000300647","article-title":"When do levodopa motor fluctuations first appear in Parkinson's disease?","volume":"63","author":"F Stocchi","year":"2010","journal-title":"Eur Neurol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/ana.410420508","article-title":"Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias.","volume":"42","author":"P Piccini","year":"1997","journal-title":"Ann Neurol"},{"key":"ref4","first-page":"569","article-title":"Effects of Opioid Antagonists on L-DOPA-Induced Dyskinesia in Parkinson's Disease.","author":"SH Fox","year":"2009"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1006\/exnr.2001.7727","article-title":"Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.","volume":"171","author":"B Henry","year":"2001","journal-title":"Exp Neurol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S0014-4886(03)00107-9","article-title":"Effect of acute and chronic administration of U50,488, a kappa opioid receptor agonist, in 6-OHDA-lesioned rats chronically treated with levodopa.","volume":"183","author":"C Marin","year":"2003","journal-title":"Exp Neurol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.expneurol.2007.01.024","article-title":"The selective kappa-opioid receptor agonist U50,488 reduces L-dopa-induced dyskinesias but worsens parkinsonism in MPTP-treated primates.","volume":"205","author":"H Cox","year":"2007","journal-title":"Exp Neurol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/mds.870090410","article-title":"Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease.","volume":"9","author":"O Rascol","year":"1994","journal-title":"Mov Disord"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.nbd.2004.02.002","article-title":"The opioid agonist morphine decreases the dyskinetic response to dopaminergic agents in parkinsonian monkeys.","volume":"16","author":"P Samadi","year":"2004","journal-title":"Neurobiol Dis"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/S0028-3908(03)00249-1","article-title":"Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems.","volume":"45","author":"P Samadi","year":"2003","journal-title":"Neuropharmacology"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/jms.754","article-title":"Altered extracellular striatal in vivo biotransformation of the opioid neuropeptide dynorphin A(1-17) in the unilateral 6-OHDA rat model of Parkinson's disease.","volume":"40","author":"R Klintenberg","year":"2005","journal-title":"J Mass Spectrom"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/mds.10693","article-title":"Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease.","volume":"19","author":"S Fox","year":"2004","journal-title":"Mov Disord"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.nbd.2009.02.002","article-title":"De novo and long-term l-Dopa induce both common and distinct striatal gene profiles in the hemiparkinsonian rat.","volume":"34","author":"M El Atifi-Borel","year":"2009","journal-title":"Neurobiol Dis"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1046\/j.1460-9568.1998.00285.x","article-title":"L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA.","volume":"10","author":"MA Cenci","year":"1998","journal-title":"Eur J Neurosci"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0014-2999(82)90477-0","article-title":"Immunohistochemical evidence for a dynorphin immunoreactive striato-nigral pathway.","volume":"85","author":"S Vincent","year":"1982","journal-title":"Eur J Pharmacol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/BF00238213","article-title":"Striato-nigral dynorphin and substance P pathways in the rat. I. Biochemical and immunohistochemical studies.","volume":"64","author":"I Christensson-Nylander","year":"1986","journal-title":"Exp Brain Res"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1073\/pnas.79.9.3062","article-title":"Immunohistochemical distribution of alpha-neo-endorphin\/dynorphin neuronal systems in rat brain: evidence for colocalization.","volume":"79","author":"E Weber","year":"1982","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/0143-4179(85)90137-4","article-title":"Dynorphin peptides in human substantia nigra.","volume":"6","author":"I Christensson-Nylander","year":"1985","journal-title":"Neuropeptides"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/0006-8993(90)90977-J","article-title":"Regulation of striatonigral prodynorphin peptides by dopaminergic agents.","volume":"518","author":"KA Trujillo","year":"1990","journal-title":"Brain Res"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/0006-8993(84)90133-1","article-title":"Primate model of Parkinson's disease: alterations in multiple opioid systems in the basal ganglia.","volume":"322","author":"N Zamir","year":"1984","journal-title":"Brain Res"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"4751","DOI":"10.1021\/ac970888i","article-title":"Molecular imaging of biological samples: localization of peptides and proteins using MALDI-TOF MS.","volume":"69","author":"RM Caprioli","year":"1997","journal-title":"Anal Chem"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nmeth1145","article-title":"Imaging mass spectrometry of proteins and peptides: 3D volume reconstruction.","volume":"5","author":"M Andersson","year":"2008","journal-title":"Nat Methods"},{"key":"ref23","article-title":"The Rat Brain in Stereotaxic Coordinates","author":"G Paxinos","year":"2007"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0028-3908(00)00005-8","article-title":"CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury.","volume":"39","author":"T Schallert","year":"2000","journal-title":"Neuropharmacology"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1523\/JNEUROSCI.21-12-04427.2001","article-title":"Forced limb-use effects on the behavioral and neurochemical effects of 6-hydroxydopamine.","volume":"21","author":"JL Tillerson","year":"2001","journal-title":"J Neurosci"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S0169-328X(00)00264-3","article-title":"Generation of dynorphin knockout mice.","volume":"86","author":"N Sharifi","year":"2001","journal-title":"Brain Res Mol Brain Res"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ijms.2006.10.005","article-title":"Processing MALDI Mass Spectra to Improve Mass Spectral Direct Tissue Analysis.","volume":"260","author":"JL Norris","year":"2007","journal-title":"Int J Mass Spectrom"},{"key":"ref28","author":"H Li"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/0024-3205(83)90703-8","article-title":"An ion exchange chromatography and radioimmunoassay procedure for measuring opioid peptides and substance P.","volume":"33","author":"L Bergstrom","year":"1983","journal-title":"Life Sci"},{"key":"ref30","first-page":"125","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing.","author":"Y Benjamini","year":"1995"},{"key":"ref31","article-title":"R: A language and environment for statistival computing.","year":"2008"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"Article3","DOI":"10.2202\/1544-6115.1027","article-title":"Linear models and empirical bayes methods for assessing differential expression in microarray experiments.","volume":"3","author":"GK Smyth","year":"2004","journal-title":"Stat Appl Genet Mol Biol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1021\/pr060690r","article-title":"Optimization of neuropeptide extraction from the mouse hypothalamus.","volume":"6","author":"FY Che","year":"2007","journal-title":"J Proteome Res"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1039\/c003317k","article-title":"Analysis of mouse brain peptides using mass spectrometry-based peptidomics: implications for novel functions ranging from non-classical neuropeptides to microproteins.","volume":"6","author":"LD Fricker","year":"2010","journal-title":"Mol Biosyst"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0014-2999(82)90433-2","article-title":"Des-tyrosine-dynorphin antagonizes morphine analgesia.","volume":"85","author":"JM Walker","year":"1982","journal-title":"Eur J Pharmacol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1073\/pnas.80.4.1125","article-title":"Immunohistochemical distribution of dynorphin B in rat brain: relation to dynorphin A and alpha-neo-endorphin systems.","volume":"80","author":"E Weber","year":"1983","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2174\/138945007779315597","article-title":"Peptide conversion--a potential pathway modulating G-protein signaling.","volume":"8","author":"F Nyberg","year":"2007","journal-title":"Curr Drug Targets"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"11082","DOI":"10.1016\/S0021-9258(18)60430-2","article-title":"A novel bovine spinal cord endoprotease with high specificity for dynorphin B.","volume":"264","author":"J Silberring","year":"1989","journal-title":"J Biol Chem"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0006-8993(95)00928-J","article-title":"The cloned mu, delta and kappa receptors and their endogenous ligands: evidence for two opioid peptide recognition cores.","volume":"700","author":"A Mansour","year":"1995","journal-title":"Brain Res"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0196-9781(97)00025-9","article-title":"Differential metabolism of dynorphins in substantia nigra, striatum, and hippocampus.","volume":"18","author":"J Sandin","year":"1997","journal-title":"Peptides"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0143-4179(97)90072-X","article-title":"A comparison between microwave irradiation and decapitation: basal levels of dynorphin and enkephalin and the effect of chronic morphine treatment on dynorphin peptides.","volume":"31","author":"I Nylander","year":"1997","journal-title":"Neuropeptides"},{"key":"ref42","article-title":"L-DOPA-induced dyskinesia is associated with regional increase of striatal dynorphin peptides as elucidated by imaging mass spectrometry.","author":"J Hanrieder","year":"2011","journal-title":"Mol Cell Proteomics"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1212\/WNL.45.8.1613","article-title":"Long-duration response to levodopa.","volume":"45","author":"JG Nutt","year":"1995","journal-title":"Neurology"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/ana.410380308","article-title":"The subacute levodopa test for evaluating long-duration response in Parkinson's disease.","volume":"38","author":"A Quattrone","year":"1995","journal-title":"Ann Neurol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s11095-006-9202-3","article-title":"Levodopa slows progression of Parkinson's disease: external validation by clinical trial simulation.","volume":"24","author":"PL Chan","year":"2007","journal-title":"Pharm Res"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1212\/WNL.0b013e318198e0e9","article-title":"Mechanisms compensating for dopamine loss in early Parkinson disease.","volume":"72","author":"J Brotchie","year":"2009","journal-title":"Neurology"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0022-3565(24)29483-0","article-title":"Femtomolar concentrations of dynorphins protect rat mesencephalic dopaminergic neurons against inflammatory damage.","volume":"298","author":"B Liu","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/0306-4522(94)00606-6","article-title":"Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson's disease.","volume":"66","author":"AP Nisbet","year":"1995","journal-title":"Neuroscience"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/jnen\/61.2.186","article-title":"Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias.","volume":"61","author":"F Calon","year":"2002","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0014-4886(03)00064-5","article-title":"Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease.","volume":"183","author":"B Henry","year":"2003","journal-title":"Exp Neurol"},{"key":"ref51","first-page":"569","article-title":"Effects of Opioid Antagonists on L-DOPA-Induced Dyskinesia in Parkinson's Disease.","author":"SH Fox","year":"2009"},{"key":"ref52","first-page":"S22","article-title":"Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model.","volume":"47","author":"JA Obeso","year":"2000","journal-title":"Ann Neurol"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1006\/nbdi.1999.0259","article-title":"Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease.","volume":"6","author":"M Andersson","year":"1999","journal-title":"Neurobiol Dis"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1471-4159.2006.03732.x","article-title":"Big dynorphin as a putative endogenous ligand for the kappa-opioid receptor.","volume":"97","author":"F Merg","year":"2006","journal-title":"J Neurochem"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.pharmthera.2009.05.006","article-title":"30 years of dynorphins--new insights on their functions in neuropsychiatric diseases.","volume":"123","author":"C Schwarzer","year":"2009","journal-title":"Pharmacol Ther"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1006\/nbdi.2000.0372","article-title":"Alterations in cortical and basal ganglia levels of opioid receptor binding in a rat model of l-DOPA-induced dyskinesia.","volume":"8","author":"PA Johansson","year":"2001","journal-title":"Neurobiol Dis"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.biopsych.2006.06.038","article-title":"Enhanced preproenkephalin-B-derived opioid transmission in striatum and subthalamic nucleus converges upon globus pallidus internalis in L-3,4-dihydroxyphenylalanine-induced dyskinesia.","volume":"61","author":"I Aubert","year":"2007","journal-title":"Biol Psychiatry"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/0196-9781(82)90067-5","article-title":"Endogenous ligands for kappa-opiate receptors.","volume":"3","author":"R Schulz","year":"1982","journal-title":"Peptides"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s00702-002-0715-6","article-title":"Naloxone reduces levodopa-induced dyskinesias and apomorphine-induced rotations in primate models of parkinsonism.","volume":"109","author":"R Klintenberg","year":"2002","journal-title":"J Neural Transm"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0025653","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T08:24:37Z","timestamp":1741767877000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0025653"}},"subtitle":[],"editor":[{"given":"Mal\u00fa G.","family":"Tansey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,9,30]]},"references-count":59,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2011,9,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0025653","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,30]]}}}